DE60043070D1 - Proteine-abgabe durch polare epithelzellen schichte - Google Patents

Proteine-abgabe durch polare epithelzellen schichte

Info

Publication number
DE60043070D1
DE60043070D1 DE60043070T DE60043070T DE60043070D1 DE 60043070 D1 DE60043070 D1 DE 60043070D1 DE 60043070 T DE60043070 T DE 60043070T DE 60043070 T DE60043070 T DE 60043070T DE 60043070 D1 DE60043070 D1 DE 60043070D1
Authority
DE
Germany
Prior art keywords
bioactive
epithelial cells
protein delivery
moiety
polar epithelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60043070T
Other languages
German (de)
English (en)
Inventor
David J Fitzgerald
Randall J Mrsny
Miriam Mckee
Ann Daugherty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
US Department of Health and Human Services
Original Assignee
Genentech Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, US Department of Health and Human Services filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60043070D1 publication Critical patent/DE60043070D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60043070T 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte Expired - Lifetime DE60043070D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16092399P 1999-10-22 1999-10-22
PCT/US2000/029080 WO2001030392A2 (en) 1999-10-22 2000-10-18 Delivery of proteins across polar epithelial cell layers

Publications (1)

Publication Number Publication Date
DE60043070D1 true DE60043070D1 (de) 2009-11-12

Family

ID=22579051

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60043070T Expired - Lifetime DE60043070D1 (de) 1999-10-22 2000-10-18 Proteine-abgabe durch polare epithelzellen schichte

Country Status (8)

Country Link
US (1) US7824695B1 (https=)
EP (1) EP1242122B1 (https=)
JP (2) JP2003512441A (https=)
AT (1) ATE444081T1 (https=)
AU (1) AU784657B2 (https=)
CA (1) CA2389302C (https=)
DE (1) DE60043070D1 (https=)
WO (1) WO2001030392A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510683A (ja) * 1997-07-11 2001-08-07 ザ ガバメント オブ ザ ユナイテッド ステイツ リプリゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原
EP1242122B1 (en) * 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
US7713737B2 (en) 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
CA2631981A1 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
CA2647168A1 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP4082558B1 (en) 2018-03-08 2023-08-23 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
WO1995007297A1 (en) * 1993-09-06 1995-03-16 Menarini Ricerche Sud S.P.A. Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them
DE69522216T2 (de) 1994-05-13 2002-05-02 Biovation Ltd Zielzellen-bindende chimäre Peptide
US6426075B1 (en) * 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
AU6769998A (en) * 1997-03-26 1998-10-20 Board Of Regents, The University Of Texas System Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
JP2001510683A (ja) * 1997-07-11 2001-08-07 ザ ガバメント オブ ザ ユナイテッド ステイツ リプリゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原
US20030054012A1 (en) 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6472140B1 (en) * 1997-09-05 2002-10-29 The General Hospital Corporation α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease.
EP1242122B1 (en) 1999-10-22 2009-09-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Delivery of proteins across polar epithelial cell layers
DE60029119D1 (de) 1999-10-22 2006-08-10 Us Gov Nat Inst Health Disulfidkonjugierte zellgifte und verfahren zur ihrer herstellung und verwendung
US7314625B2 (en) 2000-12-21 2008-01-01 The United States As Represented By The Secretary Of The Department Of Health And Human Services Chimeric protein comprising non-toxic Pseudomonas exotoxin A and Type IV pilin sequences

Also Published As

Publication number Publication date
ATE444081T1 (de) 2009-10-15
JP2012051939A (ja) 2012-03-15
AU1339201A (en) 2001-05-08
JP2003512441A (ja) 2003-04-02
US7824695B1 (en) 2010-11-02
CA2389302C (en) 2011-03-15
WO2001030392A2 (en) 2001-05-03
AU784657B2 (en) 2006-05-18
EP1242122B1 (en) 2009-09-30
CA2389302A1 (en) 2001-05-03
EP1242122A2 (en) 2002-09-25
WO2001030392A3 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
Niedel et al. Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
NO20063026L (no) Antistoffer
CY1118504T1 (el) Τριμερης πρωτεϊνη συντηξης του συνδετη οχ40 στην περιοχη ανοσοσφαιρινης και τροποι χρησης
DE69633617D1 (de) Il-17 receptor
ATE127153T1 (de) Zellen mit ausgestattener antikörperspezifität.
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
DE60043070D1 (de) Proteine-abgabe durch polare epithelzellen schichte
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
DK1331944T3 (da) Anvendelse af CD28-specifikke monoklonale antistoffer til stimulering af blodlegemer, der ikke bærer CD28
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
PT969873E (pt) Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
WAKSMAN Overview: Biology of the lymphokines
Pelletier et al. Down modulation of Heymann's nephritis by mercuric chloride
EP0288520A1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof.
SE9604470D0 (sv) Transmembrane component of tight junction
EP0725081A4 (en) MONOCLONAL ANTIBODY AGAINST MxA OF HUMAN Mx PROTEIN
BR9105717A (pt) Receptor poli-ig sintetico,complexos de receptor-anticorpo,sua producao e uso
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
ES2122921B1 (es) Proteinas recombinantes de fusion del virus reproductivo y respiratorio porcino (prrsv) y su empleo en diagnostico.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition